Novel histone modifications and liver cancer: emerging frontiers in epigenetic regulation.

IF 4.8 2区医学 Q1 GENETICS & HEREDITY

Clinical Epigenetics Pub Date : 2025-02-20 DOI:10.1186/s13148-025-01838-8

Zhonghua Wang, Ziwen Liu, Mengxin Lv, Zhou Luan, Tao Li, Jinhua Hu

{"title":"Novel histone modifications and liver cancer: emerging frontiers in epigenetic regulation.","authors":"Zhonghua Wang, Ziwen Liu, Mengxin Lv, Zhou Luan, Tao Li, Jinhua Hu","doi":"10.1186/s13148-025-01838-8","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide, and its onset and progression are closely associated with epigenetic modifications, particularly post-translational modifications of histones (HPTMs). In recent years, advances in mass spectrometry (MS) have revealed a series of novel HPTMs, including succinylation (Ksuc), citrullination (Kcit), butyrylation (Kbhb), lactylation (Kla), crotonylation (Kcr), and 2-hydroxyisobutyrylation (Khib). These modifications not only expand the histone code but also play significant roles in key carcinogenic processes such as tumor proliferation, metastasis, and metabolic reprogramming in HCC. This review provides the first comprehensive analysis of the impact of novel HPTMs on gene expression, cellular metabolism, immune evasion, and the tumor microenvironment. It specifically focuses on their roles in promoting tumor stem cell characteristics, epithelial-mesenchymal transition (EMT), and therapeutic resistance. Additionally, the review highlights the dynamic regulation of these modifications by specific enzymes, including \"writers,\" \"readers,\" and \"erasers.\"</p>","PeriodicalId":10366,"journal":{"name":"Clinical Epigenetics","volume":"17 1","pages":"30"},"PeriodicalIF":4.8000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11841274/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Epigenetics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13148-025-01838-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide, and its onset and progression are closely associated with epigenetic modifications, particularly post-translational modifications of histones (HPTMs). In recent years, advances in mass spectrometry (MS) have revealed a series of novel HPTMs, including succinylation (Ksuc), citrullination (Kcit), butyrylation (Kbhb), lactylation (Kla), crotonylation (Kcr), and 2-hydroxyisobutyrylation (Khib). These modifications not only expand the histone code but also play significant roles in key carcinogenic processes such as tumor proliferation, metastasis, and metabolic reprogramming in HCC. This review provides the first comprehensive analysis of the impact of novel HPTMs on gene expression, cellular metabolism, immune evasion, and the tumor microenvironment. It specifically focuses on their roles in promoting tumor stem cell characteristics, epithelial-mesenchymal transition (EMT), and therapeutic resistance. Additionally, the review highlights the dynamic regulation of these modifications by specific enzymes, including "writers," "readers," and "erasers."

查看原文本刊更多论文

新型组蛋白修饰与肝癌：表观遗传调控的新兴前沿。

肝细胞癌（HCC）是全球癌症相关死亡的主要原因之一，其发病和进展与表观遗传修饰，特别是组蛋白翻译后修饰（HPTMs）密切相关。近年来，质谱（MS）技术的进步揭示了一系列新的HPTMs，包括琥珀酰化（Ksuc）、瓜氨酸化（Kcit）、丁基化（Kbhb）、乳酸化（Kla）、巴豆醇化（Kcr）和2-羟基异丁基化（Khib）。这些修饰不仅扩展了组蛋白编码，而且在HCC的肿瘤增殖、转移和代谢重编程等关键致癌过程中发挥重要作用。这篇综述首次全面分析了新型hptm对基因表达、细胞代谢、免疫逃避和肿瘤微环境的影响。它特别关注它们在促进肿瘤干细胞特性、上皮-间质转化（EMT）和治疗耐药性中的作用。此外，该综述还强调了特定酶对这些修饰的动态调节，包括“写入器”、“读取器”和“擦除器”。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Epigenetics ONCOLOGY-

自引率

5.30%

发文量

150

期刊介绍： Clinical Epigenetics, the official journal of the Clinical Epigenetics Society, is an open access, peer-reviewed journal that encompasses all aspects of epigenetic principles and mechanisms in relation to human disease, diagnosis and therapy. Clinical trials and research in disease model organisms are particularly welcome.